» Articles » PMID: 31673241

Caveolin-1 and MLRs: A Potential Target for Neuronal Growth and Neuroplasticity After Ischemic Stroke

Overview
Journal Int J Med Sci
Specialty General Medicine
Date 2019 Nov 2
PMID 31673241
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Ischemic stroke is a leading cause of morbidity and mortality worldwide. Thrombolytic therapy, the only established treatment to reduce the neurological deficits caused by ischemic stroke, is limited by time window and potential complications. Therefore, it is necessary to develop new therapeutic strategies to improve neuronal growth and neurological function following ischemic stroke. Membrane lipid rafts (MLRs) are crucial structures for neuron survival and growth signaling pathways. Caveolin-1 (Cav-1), the main scaffold protein present in MLRs, targets many neural growth proteins and promotes growth of neurons and dendrites. Targeting Cav-1 may be a promising therapeutic strategy to enhance neuroplasticity after cerebral ischemia. This review addresses the role of Cav-1 and MLRs in neuronal growth after ischemic stroke, with an emphasis on the mechanisms by which Cav-1/MLRs modulate neuroplasticity via related receptors, signaling pathways, and gene expression. We further discuss how Cav-1/MLRs may be exploited as a potential therapeutic target to restore neuroplasticity after ischemic stroke. Finally, several representative pharmacological agents known to enhance neuroplasticity are discussed in this review.

Citing Articles

Exploration of the Molecular Mechanism by Which Caveolin-1 Regulates Changes in Blood-Brain Barrier Permeability Leading to Eosinophilic Meningoencephalitis.

Chen A, Lai S, Lu C, Chen K Trop Med Infect Dis. 2024; 9(6).

PMID: 38922036 PMC: 11209224. DOI: 10.3390/tropicalmed9060124.


Desflurane improves electrical activity of neurons and alleviates oxygen-glucose deprivation-induced neuronal injury by activating the Kcna1-dependent Kv1.1 channel.

Ni X, Yu X, Ye Q, Su X, Shen S Exp Brain Res. 2024; 242(2):477-490.

PMID: 38184806 DOI: 10.1007/s00221-023-06764-w.


Are There Lipid Membrane-Domain Subtypes in Neurons with Different Roles in Calcium Signaling?.

Samhan-Arias A, Poejo J, Marques-da-Silva D, Martinez-Costa O, Gutierrez-Merino C Molecules. 2023; 28(23).

PMID: 38067638 PMC: 10708093. DOI: 10.3390/molecules28237909.


Gene therapy of adeno-associated virus (AAV) vectors in preclinical models of ischemic stroke.

Wang J, Zhu M, Sun J, Feng L, Yang M, Sun B CNS Neurosci Ther. 2023; 29(12):3725-3740.

PMID: 37551863 PMC: 10651967. DOI: 10.1111/cns.14392.


Effect of liver X receptor agonist TO901317 on cognitive function in APP/PS1 double transgenic mice with Alzheimers disease and the underlying mechanism.

Luo Y, Tan X, Zhang X, Li Y, Huang J, Deng Y Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(10):1324-1331.

PMID: 36411683 PMC: 10930358. DOI: 10.11817/j.issn.1672-7347.2022.210770.


References
1.
Kwon H, Jeong K, Hwang E, Park J, Pak Y . A novel domain of caveolin-2 that controls nuclear targeting: regulation of insulin-specific ERK activation and nuclear translocation by caveolin-2. J Cell Mol Med. 2010; 15(4):888-908. PMC: 3922675. DOI: 10.1111/j.1582-4934.2010.01079.x. View

2.
Dias G, Cocks G, do Nascimento Bevilaqua M, Nardi A, Thuret S . Resveratrol: A Potential Hippocampal Plasticity Enhancer. Oxid Med Cell Longev. 2016; 2016:9651236. PMC: 4897722. DOI: 10.1155/2016/9651236. View

3.
Bockaert J, Perroy J, Becamel C, Marin P, Fagni L . GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies. Annu Rev Pharmacol Toxicol. 2010; 50:89-109. DOI: 10.1146/annurev.pharmtox.010909.105705. View

4.
Hermann D, Zechariah A, Kaltwasser B, Bosche B, Caglayan A, Kilic E . Sustained neurological recovery induced by resveratrol is associated with angioneurogenesis rather than neuroprotection after focal cerebral ischemia. Neurobiol Dis. 2015; 83:16-25. DOI: 10.1016/j.nbd.2015.08.018. View

5.
Tahir S, Park S, Thompson T . Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther. 2009; 8(23):2286-96. PMC: 2887683. DOI: 10.4161/cbt.8.23.10138. View